Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 427

1.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003. Epub 2013 May 23.

2.

Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.

Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.

Cancer Cytopathol. 2015 Oct;123(10):593-602. doi: 10.1002/cncy.21586. Epub 2015 Jul 31.

3.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
4.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

5.

MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.

Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E.

Thyroid. 2014 Sep;24(9):1375-84. doi: 10.1089/thy.2013.0594. Epub 2014 Aug 1.

PMID:
25012490
6.

Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A.

J Clin Endocrinol Metab. 2013 May;98(5):E934-42. doi: 10.1210/jc.2012-3930. Epub 2013 Mar 26.

PMID:
23533235
7.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10. Epub 2012 Mar 17.

PMID:
22426956
8.

Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.

Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN.

Surgery. 2013 Dec;154(6):1199-204; discussion 1204-5. doi: 10.1016/j.surg.2013.06.020. Epub 2013 Aug 6.

9.

[Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].

Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.

Zhonghua Zhong Liu Za Zhi. 2017 May 23;39(5):361-366. doi: 10.3760/cma.j.issn.0253-3766.2017.05.008. Chinese.

PMID:
28535653
10.

Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.

Yim JH, Kim WG, Jeon MJ, Han JM, Kim TY, Yoon JH, Hong SJ, Song DE, Gong G, Shong YK, Kim WB.

Thyroid. 2014 Apr;24(4):689-94. doi: 10.1089/thy.2012.0585. Epub 2013 Dec 13.

11.

Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.

Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.

JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1164-70. doi: 10.1001/jamaoto.2013.4501.

PMID:
24030686
12.

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ 3rd, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.

Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7.

13.

Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.

Min HS, Lee C, Jung KC.

J Korean Med Sci. 2013 Apr;28(4):534-41. doi: 10.3346/jkms.2013.28.4.534. Epub 2013 Mar 27.

14.

Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.

Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY.

Thyroid. 2013 Nov;23(11):1423-30. doi: 10.1089/thy.2013.0036. Epub 2013 Sep 27.

PMID:
23496275
15.

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.

Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.

Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x.

PMID:
22702340
16.

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.

Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, Asahina M, Yamashita A, Tomomasa R, Hayashi T, Arakawa A, Yao T.

Virchows Arch. 2016 Dec;469(6):687-696. Epub 2016 Oct 7.

PMID:
27718012
17.

Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.

Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.

Eur J Endocrinol. 2013 Apr 15;168(5):675-81. doi: 10.1530/EJE-12-1029. Print 2013 May.

18.

Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.

Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ 3rd, Zarnegar R.

Ann Surg Oncol. 2012 Mar;19(3):973-80. doi: 10.1245/s10434-011-2029-0. Epub 2011 Aug 31.

PMID:
21879273
19.

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P.

J Clin Endocrinol Metab. 2010 Sep;95(9):4197-205. doi: 10.1210/jc.2010-0337. Epub 2010 Jul 14.

PMID:
20631031
20.

BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.

Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.

Cancer. 2007 Sep 15;110(6):1218-26.

Supplemental Content

Support Center